Alvotech ALVO

NAS: ALVO | ISIN: LU2458332611 13/11/2026

4,190 USD (-10,28%)

(-10,28%) 13/11/2026

Grafiek Alvotech

Grafiek Alvotech

1 dag1d -10,28%
1 week1w -10,66%
1 maand1m -21,09%
3 maanden3m 7,99%
6 maanden6m 26,59%
1 jaar1j -18,48%
5 jaar5j -62,56%

Alvotech in het nieuws

Toon enkel gratis nieuws

11 november 2026 · Alvotech Announces Financial Results for the Nine Months to September 30, 2026, with a Business Update · Persbericht

2 november 2026 · Alvotech to Present at Upcoming Investor Conferences in November · Persbericht

28 oktober 2026 · Alvotech to Report Financial Results for the Nine-Month Period to September 30, 2026 · Persbericht

20 oktober 2026 · Alvotech receives FDA approval for new SIMLANDI® manufacturing process that more than doubles output per batch · Persbericht

14 oktober 2026 · Alvotech and Advanz Pharma announce first known regulatory submission worldwide for proposed biosimilar to Eylea® 8 mg · Persbericht

6 oktober 2026 · Alvotech and LOTTE Biologics announce US-based manufacturing agreement to increase global supply · Persbericht

5 oktober 2026 · FDA approves additional U.S. manufacturing capacity for SIMLANDI®, Alvotech’s biosimilar to Humira® · Persbericht

31 augustus 2026 · Alvotech announces FDA acceptance for review of Biologics License Application for AVT80, expanding proposed biosimilar program for Entyvio® to subcutaneous presentations · Persbericht

27 augustus 2026 · Alvotech to present at upcoming investor conferences in September · Persbericht

21 augustus 2026 · Alvotech Announces Licensing and Commercialization Agreement with Lotus Pharmaceutical for proposed biosimilars to durvalumab and emicizumab in the U.S. and Selected Asian Markets · Persbericht

Mijn selecties

Je selectie is nog leeg.

Voeg nu effecten toe